The U.S. Department of Defense is seeking information from organizations on their capability to support advanced development of human butyrylcholinesterase (HuBChE) as a medical countermeasure.
Overseen by the Joint Product Manager – Medical Countermeasure Systems (JPM-MCS) and executed by the prime contractor Dynport Vaccine Company LLC (DVC), a subcontractor is sought to perform half maximal inhibitory concentration (IC50) determinations for Guinea Pig, Rhesus Macaque and Human Erythrocyte-associated Acetylcholinesterase (AChE) exposed to organophosphate nerve agents (GD and VX).
Respondents must have appropriate safety practices in place to handle organophosphate nerve agents; demonstrated ability to perform in vitro enzyme inhibition studies; and the demonstrated ability to produce data and documentation for submission to the FDA in support of product licensure.
Further details are available via Solicitation Number: W911QY-16-S-0001. The response deadline is February 12, 2016.
